Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma

Blackley, Elizabeth F.; Lim, Lisi Elizabeth; Moore, Miranda; Voskoboynik, Mark; McLean, Catriona; Haydon, Andrew

doi:10.1093/annonc/mdx377.028

Cited by 4 publications

(3 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This would support our results because T-cell infiltration is a key element for an appropriate immune response against the tumor. Nevertheless, other studies found a correlation between ANC/ALC and patient outcome regardless of the treatment (52,53).…”

Section: Discussionmentioning

confidence: 84%

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Hogan

Courtier²,

Cheng

et al. 2019

Cancer Immunology Research

123

104

View full text Add to dashboard Cite

Many metastatic melanoma patients experience durable responses to anti-PD1 and/or anti-CTLA4; however, a significant proportion (over 50%) do not benefit from the therapies. In this study, we sought to assess pretreatment liquid biopsies for biomarkers that may correlate with response to checkpoint blockade. We measured the combinatorial diversity evenness of the T-cell receptor (TCR) repertoire (the DE 50 , with low values corresponding to more clonality and lack of TCR diversity) in pretreatment peripheral blood mononuclear cells from melanoma patients treated with anti-CTLA4 (n ¼ 42) or anti-PD1 (n ¼ 38) using a multi-N-plex PCR assay on genomic DNA (gDNA). A receiver operating characteristic curve determined the optimal threshold for a dichotomized analysis according to objective responses as defined by RECIST1.1. Correlations between treatment outcome, clinical variables, and DE 50 were assessed in multivariate regression models and confirmed with Fisher exact tests. In samples obtained prior to treatment initiation, we showed that low DE 50 values were predictive of a longer progression-free survival and good responses to PD-1 blockade, but, on the other hand, predicted a poor response to CTLA4 inhibition. Multivariate logistic regression models identified DE 50 as the only independent predictive factor for response to anti-CTLA4 therapy (P ¼ 0.03) and anti-PD1 therapy (P ¼ 0.001). Fisher exact tests confirmed the association of low DE 50 with response in the anti-CTLA4 (P ¼ 0.041) and the anti-PD1 cohort (P ¼ 0.0016). Thus, the evaluation of basal TCR repertoire diversity in peripheral blood, using a PCRbased method, could help predict responses to anti-PD1 and anti-CTLA4 therapies.

show abstract

Section: Discussionmentioning

confidence: 84%

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Hogan

Courtier²,

Cheng

et al. 2019

Cancer Immunology Research

123

104

View full text Add to dashboard Cite

show abstract

“…Because this ratio was first presented as a simple tool to measure the intensity of stress and systemic inflammation in critically ill patients [57] and because high counts of neutrophils in blood had already been confirmed as an independent predictive factor in cancer patients [58], Walsh et al decided to evaluate its prognostic value in colorectal cancer patients and concluded that a preoperative NLR greater than five was correlated with a poorer survival [59]. It was also demonstrated in metastatic melanoma patients that an NLR > 5 was an independent biomarker of a poor prognosis, whatever the treatment received [60]. In an NSCLC adjuvant setting, it has then been shown that the NLR was associated with a higher stage and could be used as a predictive biomarker of survival [61].…”

Section: The Neutrophil/lymphocyte Ratiomentioning

confidence: 99%

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

Pabst

Lopes

Bertrand

et al. 2023

IJMS

View full text Add to dashboard Cite

The therapeutic algorithm of lung cancer has recently been revolutionized by the emergence of immune checkpoint inhibitors. However, an objective and durable response rate remains low with those recent therapies and some patients even experience severe adverse events. Prognostic and predictive biomarkers are therefore needed in order to select patients who will respond. Nowadays, the only validated biomarker is the PD-L1 expression, but its predictive value remains imperfect, and it does not offer any certainty of a sustained response to treatment. With recent progresses in molecular biology, genome sequencing techniques, and the understanding of the immune microenvironment of the tumor and its host, new molecular features have been highlighted. There are evidence in favor of the positive predictive value of the tumor mutational burden, as an example. From the expression of molecular interactions within tumor cells to biomarkers circulating in peripheral blood, many markers have been identified as associated with the response to immunotherapy. In this review, we would like to summarize the latest knowledge about predictive and prognostic biomarkers of immune checkpoint inhibitors efficacy in order to go further in the field of precision immuno-oncology.

show abstract

“…Des biomarqueurs circulants peuvent être utilisés pour prédire la réponse à l'immunothérapie, le plus connu étant le rapport neutrophiles/lymphocytes, dont le taux élevé est prédictif de mauvaise réponse dans différents types de cancers tels que le CBNPC [23] ou le mélanome [24]. Le (Lung Immune Prognostic Index), qui combine le rapport neutrophiles/lymphocytes et la protéine C réactive (CRP), a montré dans le CBNPC un impact pronostique pour la réponse aux inhibiteurs de checkpoints immunitaires [25].…”

Section: Autres Biomarqueursunclassified

Toxicités sévères des immunothérapies du cancer

Assoun¹,

Becourt²,

Nguyen

et al. 2018

Méd. Intensive Réa.

View full text Add to dashboard Cite

L’immunothérapie représente une avancée récente et importante en cancérologie. Les inhibiteurs de checkpoints immunitaires, ciblant les protéines PD-1, PD-L1 et CTLA-4, sont les thérapies les plus prometteuses et sont utilisés dans la prise en charge de plusieurs cancers. Les toxicités associées à ces traitements sont généralement moins fréquentes et moins graves que celles associées aux chimiothérapies et à la plupart des thérapies ciblées. Cependant, il existe un certain nombre de toxicités spécifiques de ce type de traitement, qui peuvent parfois être sévères et dont les plus fréquentes sont les toxicités pulmonaire, digestive, endocrinienne et cutanée. Dans cette mise au point, nous reviendrons sur la fréquence, le mécanisme et les principes de traitement des différentes toxicités sévères associées à l’immunothérapie.

show abstract

Neutrophil to Lymphocyte Ratio (NLR) as an independent prognostic measure in patients receiving targeted therapy or immunotherapy for stage IV melanoma

Cited by 4 publications

References 0 publications

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Peripheral Blood TCR Repertoire Profiling May Facilitate Patient Stratification for Immunotherapy against Melanoma

Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer

Toxicités sévères des immunothérapies du cancer

Contact Info

Product

Resources

About